Aurora Investment Counsel’s Halozyme HALO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.19M Sell
18,452
-6,583
-26% -$464K 0.66% 82
2025
Q4
$1.68M Sell
25,035
-1,899
-7% -$128K 0.89% 62
2025
Q3
$1.98M Sell
26,934
-6,054
-18% -$402K 1.03% 46
2025
Q2
$1.72M Sell
32,988
-761
-2% -$43.3K 0.9% 58
2025
Q1
$2.15M Sell
33,749
-1,369
-4% -$79.5K 1.19% 29
2024
Q4
$1.68M Buy
35,118
+2,768
+9% +$142K 0.92% 56
2024
Q3
$1.85M Sell
32,350
-12,753
-28% -$731K 1% 47
2024
Q2
$2.36M Buy
45,103
+154
+0.3% +$6.75K 1.39% 14
2024
Q1
$1.83M Buy
44,949
+7,793
+21% +$292K 1.05% 40
2023
Q4
$1.61M Buy
37,156
+1,895
+5% +$71.4K 1.04% 38
2023
Q3
$1.35M Buy
+35,261
New +$1.44M 0.89% 55

Other funds holding HALO

Aurora Investment Counsel's HALO Position: Q1 2026 in Review

Aurora Investment Counsel reduced its Halozyme (HALO) stake by 26% in Q1 2026, selling an estimated $464K and leaving 18,452 shares worth $1.19M. The position accounts for 0.66% of the portfolio, ranked #82.

Aurora Investment Counsel first reported a position in HALO in Q3 2023 and has held it in 11 quarters since. The position peaked at $2.36M in Q2 2024. 635 funds tracked by Wall St. Rank hold HALO as of Q1 2026.

  • Aurora Investment Counsel held 18,452 shares of Halozyme worth $1.19M as of Q1 2026.
  • Aurora Investment Counsel sold 6,583 Halozyme shares in Q1 2026, an estimated $464K.
  • Halozyme made up 0.66% of Aurora Investment Counsel's portfolio in Q1 2026, its #82 holding.
  • Aurora Investment Counsel first reported a position in Halozyme in Q3 2023 and has held it in 11 quarters since.
  • Aurora Investment Counsel's Halozyme position peaked at $2.36M in Q2 2024.
  • 635 funds tracked by Wall St. Rank held Halozyme as of Q1 2026.

Based on Aurora Investment Counsel's 13F filing for Q1 2026, filed 6 May 2026.